



Paola Rogliani, MD
Associate Professor
Respiratory Medicine

Department of Systems Medicine
University of Rome "Tor Vergata"
Via Montpellier, 1 - 00133-
Rome, Italy
paola.rogliani@uniroma2.it

ph.: +39062090.3616/.4656

Date of Birth: September 19th 1970
Place of Birth: Napoli, Italy
Citizenship: Italian
Status: Married with two children

Education

October 1994 M.D., summa cum laude, at the University of Rome "Tor Vergata".
December 1994 Italian State Board of Medicine, University of Napoli "Federico II",
50/50 cum laude.
November 1998 Diplomate in "Respiratory Medicine" at the University of Rome "Tor
Vergata" 70/70 cum laude.

Present Position

- Head of Clinical Respiratory Unit, Policlinico Tor Vergata, Rome Italy
- Director of the Postgraduate School in "Respiratory Medicine" University of Rome "Tor Vergata"

Employment

1997- 1998 Visiting Reasearch Fellow, Pulmonary and Critical Care Medicine Branch, National Heart Lung and Blood Institute, National Institute of Health (NIH) Bethesda, MD –USA- (Dr. Joel Moss).

1998- 2000 Visiting Research Fellow, Laboratory of Molecular Immunology, National Heart Lung and Blood Institute, National Institute of Health (NIH) Bethesda, MD –USA- (Dr Warren J Leonard).

2000- 2012 Assistant Professor, Respiratory Medicine, Department of Internal Medicine, University of Rome “Tor Vergata”, Italy.

2000- present Clinical Associate and from 2015 Head of Clinical Respiratory Unit, UOC Malattie Respiratorie, Policlinico Tor Vergata, Roma (Italy)

2012- present Associate Professor, Respiratory Medicine, Department of Systems Medicine, University of Rome “Tor Vergata”, Italy

The scientific activities can be grouped into three main topics:

1. The co-morbidity in chronic obstructive airway disease (asthma and COPD): epidemiology and possible pathogenic mechanisms.
2. preclinical and clinical evaluation of new drugs for the treatment of chronic obstructive airway disease (COPD and asthma).
3. Structural and functional basis in the clinical management and prognosis of interstitial lung disease.

1. The co-morbidity in chronic obstructive airway disease (asthma and COPD): epidemiology and possible pathogenic mechanisms.

Patients with obstructive disease (COPD and asthma) often experience comorbid conditions. The most common comorbidities that have been associated with COPD include diseases mainly in cardiovascular and metabolic. Not only comorbidity are common but also greatly influence the prognosis of the disease and the patients' health status, changing the expected clinical results. In the literature, little has been done so far to evaluate effectively, manage and treat comorbidity in patients with obstructive airway disease.

We evaluated the associations between COPD and / or asthma and comorbidities using the national primary care database (Respir Med. 2012, Eur Respir J. 2011); Identified mechanisms / receptors involved in the bronchomotor tone adjustment (Am J Respir Cell Mol Biol 2012) associated with metabolic co-morbidities such as diabetes (Acta Diabetol. 2014); moreover we elaborated of an effective algorithm in the prevention of the risk of acute coronary disease in patients with COPD with a quick and non-invasive approach (Respir Med. 2012; Respir Med. 2015; Lancet Respir Med. 2015).

2. Preclinical and clinical evaluation of new drugs for the treatment of chronic obstructive airway disease (COPD and asthma).

More than 40 articles including original articles and reviews I have published on bronchodilators aimed at the study of the mechanisms of action both in experimental conditions and translational approach focused on patients; evaluating the onset of action of new bronchodilators and their associations (Respir Med. 2013 Jan; Respir Med. 2013 Jun; Pulm Pharmacol Ther. 2013; J Pharmacol Exp Ther. 2013; Respir

Med. 2014; Eur J Pharmacol. 2014). Validated is the clinical rationale for the use of the combination of b2-agonists, and antimuscarinic agents, however, which is the pharmacological nature, additive or synergistic, the results obtained by co-administration of B2 agonists and antimuscarinic agents is not entirely clarified. For the first time we have demonstrated pharmacological synergy between bronchodilators with different mechanisms of action by testing and verifying the effect type in an ex vivo model of human isolated bronchi and then, with a translational approach in vivo, in patients using different combinations of LABA , LAMA and ICS (Eur J Pharmacol. 2014; Respir Med. 2015; COPD. 2015; Eur J Pharmacol. 2015, Pulm Pharmacol Ther. 2015).

3. Structural and functional basis in the clinical management and prognosis of interstitial lung disease.

The management of patients with interstitial lung disease is a challenge for the clinician especially on the diagnostic and prognostic point of view. In cases where it is necessary to resolve the diagnostic dilemma with a surgical biopsy of interstitial lung disease VATS under general anesthesia is the standard procedure, however, still associated with rates of mortality and morbidity not negligible.

We hypothesized and developed a minimally invasive approach in VATS lung biopsy performed with regional anesthesia methods thus in awake patients with dramatic reduction of complications and excellent diagnostic yield (J Thorac Cardiovasc Surg. 2012; J Thorac Cardiovasc Surg. 2013; Ann Thorac Surg. 2013; Ann Transl Med. 2015). On the prognostic side we elaborated the ROSE, one multifactor score useful to stratify the risk of disease in patients with idiopathic pulmonary fibrosis, early detection and rapid disease progression, providing guidance for the management of this deadly condition. (Respir Med. 2008; Ther Adv Respir Dis. 2008; Radiology. 2010; Eur Respir J. 2012; Respir Med. 2013).

Scientific Interests

- Chronic obstructive pulmonary disease and dysmetabolism
- The co-morbidity in chronic bronchial obstructive disease (asthma and COPD): epidemiology and possible pathogenic mechanisms.
- Preclinical and clinical evaluation of new drugs for the treatment of obstructive airway disease (asthma and COPD).
- Structural and functional basis of genetic susceptibility to interstitial lung diseases
- Pulmonary emphysema: a 1-antitrypsin and neutrophil elastase inhibitor its role.

AWARD

- 2010 Best Researcher Award under 40, XI° National Congress of the Italian Respiratory Medicine Society.

Research Unit Participation

- “Genetica della cardiomiopatia ipertrofica “ Grant CNR 92. 0330711, 9303391.11
- “Role of Nitric Oxide in the pathogenesis of lung disease” Grant NIH 201 HL 02537.04 PCCMB
- “Analysis of HLA-DP association with beryllium disease susceptibility in pooled exposed population” Grant DE-FG02- 02ER63416
- “Role of peptide binding and intracellular signalling diversity of major histocompatibility complex genes in T-cell activation and differentiation in chronic granulomatous disorders” Grant (ISS-NIH) CONV.N.530/F-A15
- “Identificazione degli alretopi per i geni del Complesso Maggiore di Istocompatibilità di classe II coinvolti nella suscettibilità alla sarcoidosi e nella evoluzione fibrotica della malattia” PRIN 2004067923_006
- Chief Unit. Operativa di ricerca del progetto “Piattaforma Italiana per lo studio delle polimorbilità: scenario epidimologico, aspetti clinici e farmacologici, prospettiva di genere e contesto farmaco-economico”, ISS PROGRAMMA CCM 2012

PATENT

2012 application software for smartphones, tablets and computers, “COPDCoRi: non-invasive application for estimating and predicting the risk of coronary heart disease in patients with chronic obstructive pulmonary disease (COPD)”. (Autori: P. Rogliani, MG Matera, F Romeo, L. Calzetta; depositato alla SIAE n. 2013001671)

MEMBERSHIP

- European Respiratory Society (ERS)
- Società Italiana di Medicina Respiratoria (SIMeR)
- Elected scientific secretary “Clinical Group” term 2016/2018 Italian Society Respiratory Medicine (SIMeR),

Editorial Board

- Member of the Editorial Board of “Pulmonary Pharmacology and Therapeutics” (Elsevier)
- Member of the Editorial Board of “COPD Research and Practice” (Springer)
- Member of the Editorial Board of “ARS pneumologica” (Edizioni Internazionali S.r.l. –Divisione EDIMES – Edizioni Medico Scientifiche)

CLINICAL ACTIVITY

| | |
|---------------|--|
| 2000- 2003 | <i>Clinical associate</i> of the Clinical Respiratory disease Unit, UOC Malattie Respiratorie IRCCS ‘Lazzaro Spallanzani’, Roma, Italy |
| 2003 - 2011 | <i>Clinical associate</i> Day-Hospital on Interstitial Lung Disease, Disciplina di Malattie Respiratorie, Policlinico Tor vergata |
| 2007- 2011 | Clinical associate ambulatory of “Pulmonary Fibrosis and Rare Lung Disease” , UOC di Malattie Respiratorie,Policlinico Tor vergata |
| 2011- 2013 | Clinical associate of the Clinical Respiratory disease Unit, UOC di Malattie Respiratorie Policlinico Tor Vergata, Roma |
| 2006- present | <i>Chief of</i> “Bronchoscopy Unit”, UOC di Malattie Respiratorie Policlinico Tor vergata |
| 2015- present | Head of Clinical Respiratory Unit, Policlinico Tor Vergata, Rome Italy |

TEACHING ACTIVITY

| | |
|---------------|--|
| 2013- 2015 | Director of the Postgraduate School in "Sports Medicine" University of Rome "Tor Vergata" |
| 2015- present | Director of the Postgraduate School in "Respiratory Medicine" University of Rome "Tor Vergata" |

1999-present

- Teaching appointment of Respiratory Physiology (module), Integrated Course Systematic Pathology I, at the Degree in Medicine and Surgery, University of Rome "Tor Vergata"
- Teaching appointment of Respiratory Diseases within the degree in Rehabilitation Sciences, University of Rome "Tor Vergata"
- Teaching appointment of Respiratory Diseases within the degree in Science in Nursing, University of Rome "Tor Vergata"

Teaching appointment of Clinical Methodology and Respiratory Diseases at the Postgraduate School in 'Respiratory Diseases', University of Rome "Tor Vergata"

Teaching appointment of Respiratory Diseases at the Postgraduate School in 'Endocrinology and Metabolic Diseases', University of Rome "Tor Vergata"

Teaching appointment of Respiratory Rehabilitation at the Postgraduate School in 'Cardiology', University of Rome "Tor Vergata"

Teaching appointment of Respiratory Diseases at the Postgraduate School in 'Internal Medicine', University of Rome "Tor Vergata"

Teaching appointment of Respiratory Diseases at the Postgraduate School in 'Thoracic Surgery', University of Rome "Tor Vergata"

Teaching appointment of Respiratory Diseases at the Postgraduate School in 'Geriatrics, University of Rome "Tor Vergata"

Publications:

- 1) Maione F, Iaccarino F, Sirignano M, Rogliani P, Della Pietra F. "Studio di una variante di alpha1- Antitripsina". Acc. Di Scienza Mediche e Chirurgiche (Vol CXL VII feb. 1993)
- 2) Rossi P. - Senis L. - Contini A. - Nardecchia B. - Rogliani P. - Bisogni V. - Rossi S. "Osservazioni clinico-epidemiologiche sulla tubercolosi polmonare nei pazienti extracomunitari ricoverati". Igiene e Sanità Pubblica, vol. 52, n. 4, luglio-agosto 1996, pp. 271-280.
- 3) Di Nardo P, Fiaccavento R, Natali A, Minieri M, Sampaolesi M, Fusco A, Janmot C, Cuda G, Carbone A, Rogliani P, Peruzzi G. "Embryonic gene expression in nonoverloaded ventricles of hereditary hypertrophic cardiomyopathic hamsters". Lab Invest. 1997 Nov;77(5):489-502.
- 4) Mineo TC, Pompeo E, Simonetti G, Sabato AF, Turani F, Rogliani P, De Padova F, Nofroni I. "Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema". Eur J Cardiothorac Surg. 1998 Jul;14(1):33-9.
- 5) Novoradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Eissa NT, Barnes PM, Gabriele KM, Ehrmantraut ME, Rogliani P, Moss J. "Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency". Am J Respir Cell Mol Biol. 1999 Mar;20(3):441-7.
- 6) Mineo TC, Pompeo E, Rogliani P, Villaschi S, Pistolese C, Simonetti G. "Thoracoscopic reduction pneumoplasty for severe emphysema: do pleural adhesions affect outcome?" Thorac Cardiovasc Surg. 1999 Oct;47(5):288-92.
- 7) Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. "Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298". Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2832-5
- 8) Mineo TC, Pompeo E, Rogliani P, Dauri M, Turani F, Bollero P, Magliocchetti N. "Effect of lung volume reduction surgery for severe emphysema on right ventricular function".

- Am J Respir Crit Care Med. 2002 Feb 15;165(4):489-94.
- 9) Amicosante M, Berretta F, Franchi A, Rogliani P, Dotti C, Losi M, Dweik R, Saltini C. "HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells".
Eur Respir J. 2002 Nov;20(5):1174-8.
- 10) Rogliani P, Amicosante M, Berretta F, Dotti C, Bocchino M, O'Donnell KM, Saltini C. Role of the HLA-DP glu 69 and the TNF alpha TNFalpha2 gene markers in susceptibility to beryllium hypersensitivity.
Int J Immunopathol Pharmacol. 2004 May-Aug;17(2 Suppl):3-10
- 11) Dotti C, D'Apice MR, Rogliani P, Novelli G, Saltini C, Amicosante M. Analysis of TNF-alpha promoter polymorphisms in the susceptibility to beryllium hypersensitivity.
Sarcoidosis Vasc Diffuse Lung Dis. 2004 Mar;21(1):29-34)
- 12) Pompeo E, Mineo D, Bollero P, Rogliani P, Ambrogi V, Mineo TC. Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy?
J Thorac Cardiovasc Surg. 2004 Apr;127(4):1212-4.
- 13) Pompeo E, Mineo D, Rogliani P, Sabato AF, Mineo TC. Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules. Ann Thorac Surg. 2004 Nov;78(5):1761-8
- 14) Mineo TC, Pompeo E, Mineo D, Rogliani P, Leonardis C, Nofroni I. Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs.
J Thorac Cardiovasc Surg. 2005 Jan;129(1):73-9
- 15) Amicosante M, Berretta F, Rossman M, Butler RH, Rogliani P, van den Berg-Loonen E, Saltini C. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPglubeta69.
Respir Res. 2005 Aug 14;6:94.
- 16) Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD. Trends Pharmacol Sci. 2007 Oct;28(10):544-50.
- 17) Cazzola M, Rogliani P, Curradi G. Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view.
Respir Med. 2008 Mar;102(3):321-7.

- 18) Rogliani P, Mura M, Porretta MA and Saltini C. New perspectives in the treatment of idiopathic pulmonary fibrosis.
Therapeutic Advances in Respiratory Disease 2008; 2; 75
- 19) Rogliani P, Mura M, Mattia P, Ferlosio A, Farinelli G, Mariotta S, Graziano P, Pezzuto G, Ricci A, Saltini C, Orlandi A. HRCT and histopathologic evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema.
Respir Med. 2008 Dec;102(12):1753-61
- 20) Cazzola M, Mura M, Segreti A, Mattei MA, Rogliani P. Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome?
Allergy. 2009 Sep;64(9):1389-90.
- 21) Matera MG, Calzetta L, Parascandolo V, Curradi G, Rogliani P, Cazzola M. Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi.
Pulm Pharmacol Ther. 2009 Dec;22(6):478-82.
- 22) Cazzola M, Rogliani P, Curradi G, Segreti A, Ciaprinì C, Pezzuto G, Saltini C. A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. Pulm Pharmacol Ther. 2009 Dec;22(6):522-5.
- 23) Comandini A, Rogliani P, Nunziata A, Cazzola M, Curradi G, Saltini C. Biomarkers of lung damage associated with tobacco smoke in induced sputum.
Respir Med. 2009 Nov;103(11):1592-613.
- 24) Rogliani P, Curradi G, Mura M, Lauro D, Federici M, Galli A, Saltini C, Cazzola M. Metabolic syndrome and risk of pulmonary involvement.
Respir Med. 2010 Jan;104(1):47-51.
- 25) Ricci A, Mariotta S, Bronzetti E, Bruno P, Vismara L, De Dominicis C, Laganà B, Paone G, Mura M, Rogliani P, Mastrangelo M, Sciacchitano S, Saltini C. Serum CA 15-3 is increased in pulmonary fibrosis.
Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(1):54-63.
- 26) Sergiacomi G, Bolacchi F, Cadioli M, Angeli ML, Fucci F, Crusco S, Rogliani P, Pezzuto G, Romeo F, Mariano E, Simonetti G. Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement.
Radiology. 2010 Feb;254(2):601-8.

- 27) Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P. Asthma and comorbid medical illness.
Eur Respir J. 2011 Jul;38(1):42-9.
- 28) Matera MG, Calzetta L, Rogliani P, Bardaro F, Page CP, Cazzola M. Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi.
Pulm Pharmacol Ther. 2011 Apr;24(2):221-6.
- 29) Cazzola M, Segreti A, Bettoncelli G, Calzetta L, Cricelli C, Pasqua F, Rogliani P. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008.
Prim Care Respir J. 2011 Sep;20(3):291-8.
- 30) Pompeo E, Rogliani P, Tacconi F, Dauri M, Saltini C, Novelli G, Mineo TC; Awake Thoracic Surgery Research Group. Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. J Thorac Cardiovasc Surg. 2012 Jan;143(1):47-54.e1.
- 31) Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study.
Respir Med. 2012 Feb;106(2):249-56.
- 32) Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study.
Eur Respir J. 2012 Jul;40(1):101-9.
- 33) Cazzola M, Calzetta L, Rogliani P, Lauro D, Novelli L, Page CP, Kanabar V, Matera MG. High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway.
Am J Respir Cell Mol Biol. 2012 Oct;47(4):509-16.
- 34) Cazzola M, Capuano A, Rogliani P, Matera MG. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD.
Curr Opin Pharmacol. 2012 Jun;12(3):300-8.
- 35) Matera MG, Calzetta L, Passeri D, Rogliani P, Orlandi A. Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. Pulm Pharmacol Ther. 2012 Sep 21.

- 36) Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials.
Expert Opin Investig Drugs. 2012 Oct;21(10):1489-501.
- 37) Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease.
Drugs Today (Barc). 2012 Dec;48(12):785-94.
- 38) Pompeo E, Rogliani P, Cristino B, Schillaci O, Novelli G, Saltini C. Awake Thoracoscopic Biopsy of Interstitial Lung Disease.
Ann Thorac Surg. 2013 Feb;95(2):445-52.
- 39) Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
Respir Med. 2013 Jan;107(1):107-11.
- 40) Cazzola M, Segreti A, Calzetta L, Rogliani P. Comorbidities of asthma: current knowledge and future research needs.
Curr Opin Pulm Med. 2013 Jan;19(1):36-41-
- 41) Rogliani P, Calzetta L, Rendina EA, Massullo D, Dauri M, Rinaldi B, Capuano A, Matera MG. The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle.
Pulm Pharmacol Ther. 2013 Jun;26(3):325-
- 42) Cazzola M, Page CP, Rogliani P, Matera MG. β_2 -Agonist Therapy in Lung Disease.
Am J Respir Crit Care Med. 2013 Apr 1;187(7):690-6.
- 43) Segreti A, Fiori E, Calzetta L, Sabatini M, Segreti V, Rogliani P, Cazzola M. The effect of indacaterol during an acute exacerbation of COPD.
Pulm Pharmacol Ther. 2013 Apr 8.
- 44) Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
Respir Med. 2013 Jun;107(6):848-53.
- 45) Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease.
Expert Opin Pharmacother. 2013 Apr;14(6):775-81.

- 46) Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respir Med.* 2013 Jun;107(6):848-53.
- 47) Pompeo E, Dauri M; Awake Thoracic Surgery Research Group. Is there any benefit in using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis?
J Thorac Cardiovasc Surg. 2013 Aug;146(2):495-7.
- 48) Calzetta L, Passeri D, Kanabar V, Rogliani P, Page C, Cazzola M, Matera MG,Orlandi A. Brain Natriuretic Peptide Protects Against Hyperreactivityof Human Asthmatic Airway Smooth Muscle via an Epithelial Cell DependentMechanism.
Am J Respir Cell Mol Biol. 2014 Mar;50(3):493-501
- 49) Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, Matera MG. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone.
J Pharmacol Exp Ther. 2013 Sep;346(3):414-23.
- 50) Cazzola M, Calzetta L, Lauro D, Bettoncelli G, Cricelli C, Di Daniele N, Rogliani P. Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. *Respir Med.* 2013 Sep;107(9):1417-22.
- 51) Rogliani P, Ora J, Ciaprini C, Senis L, Stirpe E, Cazzola M. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. *Respir Med.* 2013 Nov 5.
- 52) Ora J, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, Portalone S, Rogliani P, Puxeddu E, Saltini C. A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD.
Respir Med. 2013 Dec;107(12):2014-21.
- 53) Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease.
Expert Opin Pharmacother. 2013 Dec;14(18):2489-99.
- 54) Segreti A, Fiori E, Calzetta L, Sabatini M, Segreti V, Rogliani P, Cazzola M. The effect of indacaterol during an acute exacerbation of COPD.
Pulm Pharmacol Ther. 2013 Dec;26(6):630-4.

- 55) Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respir Med.* 2013 Jun;107(6):848-53.
- 56) Cazzola M, Rogliani P, Matera MG. Acclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Apr;14(6):775-81.
- 57) Pompeo E, Dauri M; Awake Thoracic Surgery Research Group. Is there any benefit in using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? *J Thorac Cardiovasc Surg.* 2013 Aug;146(2):495-7.
- 58) Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, Matera MG. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. *J Pharmacol Exp Ther.* 2013 Sep;346(3):414-23.
- 59) Cazzola M, Calzetta L, Lauro D, Bettoncelli G, Cricelli C, Di Daniele N, Rogliani P. Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. *Respir Med.* 2013 Sep;107(9):1417-22.
- 60) Ora J, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, Portalone S, Rogliani P, Puxeddu E, Saltini C. A 6MWT index to predict O₂ flow correcting exercise induced SpO₂ desaturation in ILD. *Respir Med.* 2013 Dec;107(12):2014-21.
- 61) Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Dec;14(18):2489-99
- 62) Rogliani P, Ora J, Ciaprini C, Senis L, Stirpe E, Cazzola M. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. *Respir Med.* 2014 Feb;108(2):307-13.
- 63) Matera MG, Calzetta L, Rogliani P, Cesario A, Cazzola M. New Treatments for COPD in the Elderly. *Curr Pharm Des.* 2014 Mar 14
- 64) Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the

treatment of chronic obstructive pulmonary disease.

Expert Opin Pharmacother. 2014 May;15(7):961-77

- 65) Rogliani P, Calzetta L, Segreti A, Barrile A, Cazzola M. Diabetes mellitus among outpatients with COPD attending a university hospital.
Acta Diabetol. 2014 Dec;51(6):933-40
- 66) Calzetta L, Rogliani P, Cazzola M, Matera MG. Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond.
Expert Opin Drug Discov. 2014 Jun;9(6):595-607.Epub 2014 Apr 22.
- 67) Segreti A, Stirpe E, Rogliani P, Cazzola M. Defining phenotypes in COPD: an aid to personalized healthcare.
Mol Diagn Ther. 2014 Aug;18(4):381-
- 68) Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. COPD. 2014 Sep 15
- 69) Matera MG, Rogliani P, Calzetta L, Cazzola M. Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?
Drugs. 2014 Oct 10.
- 70) Segreti A, Calzetta L, Rogliani P, Cazzola M. Umeclidinium for the treatment of chronic obstructive pulmonary disease.
Expert Rev Respir Med. 2014 Oct 14:1-7.
- 71) Matera MG, Rogliani P, Rinaldi B, Cazzola M. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.
Expert Rev Clin Pharmacol. 2015 Jan;8(1):35-41.
- 72) Matera MG, Rogliani P, Cazzola M. Indacaterol for the treatment of chronic obstructive pulmonary disease.
Expert Opin Pharmacother. 2015 Jan;16(1):107-15.
- 73) Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, Matera MG. Pharmacological characterization of the interaction between acridinium bromide and formoterol fumarate on human isolated bronchi.
Eur J Pharmacol. 2014 Dec 15;745:135-43
- 74) Lipsi R, Rogliani P, Calzetta L, Segreti A, Cazzola M. The clinical use of regenerative therapy in COPD.
Int J Chron Obstruct Pulmon Dis. 2014 Dec 12;9:1389-1396.
- 75) Matera MG. Cardaci V. Cazzola M. Rogliani P. Safety of inhaled corticosteroids

for treating chronic obstructive pulmonary disease.

Expert Opin Drug Saf. 2015 Jan 5:1-9.

- 76) Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease.
Pulm Pharmacol Ther. 2015 Apr;31:15-27.
- 77) Matera MG, Rogliani P, Cazzola M. QVA149(indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.
Expert Opin Pharmacother. 2015 May;16(7):1079-90.
- 78) Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG.
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways.
Pulm Pharmacol Ther. 2015 Jun;32:15-23
- 79) Calzetta L, Luongo L, Cazzola M, Page C, Rogliani P, Facciolo F, Maione S, Capuano A, Rinaldi B, Matera MG. Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi.
Life Sci. 2015 Jun 15;131:44-50
- 80) Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera MG, Cazzola M. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015 Aug 15;761:383-90
- 81) Cazzola M, Rogliani P, Sanduzzi A, Matera MG. Influence of ethnicity on response to asthma drugs.
Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1089-97.
- 82) Ricciardolo FL, Blasi F, Centanni S, Rogliani P. Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. Pulm Pharmacol Ther. 2015 Aug;33:1-10
- 83) Pompeo E, Rogliani P, Palombi L, Orlandi A, Cristino B, Dauri M; Awake Thoracic Surgery Research Group (ATSRG). The complex care of severe emphysema: role of awake lung volume reduction surgery.
Ann Transl Med. 2015 May;3(8):108.
- 84) Pompeo E, Cristino B, Rogliani P, Dauri M; Awake Thoracic Surgery Research Group (ATSRG). Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure.

Ann Transl Med. 2015 May;3(8):112.

- 85) Cazzola M, Calzetta L, Matera MG, Muscoli S, Rogliani P, Romeo F. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. *Respir Med*. 2015 Aug;109(8):1019-25
- 86) Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. *Lancet Respir Med*. 2015 Aug;3(8):593-5
- 87) Basello K, Pacifici F, Capuani B, Pastore D, Lombardo M, Ferrelli F, Coppola A, Donadel G, Arriga R, Sconocchia G, Bellia A, Rogliani P, Federici M, Sbraccia P, Lauro D, Della-Morte D. Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial Senescence by Directly Interacting with hTERT. *Rejuvenation Res*. 2016 Feb;19(1):79-89
- 88) Cazzola M, Coppola A, Rogliani P, Matera MG. Novel glucocorticoid receptor agonists in the treatment of asthma. *Expert Opin Investig Drugs*. 2015 Nov;24(11):1473-82.
- 89) Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol*. 2015;8(5):529-39.
- 90) Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between acclidinium and formoterol: From bench to bedside. *Respir Med*. 2015 Oct;109(10):1305-11.
- 91) Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. *Drugs*. 2015 Sep;75(14):1575-85.
- 92) Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a metaanalysis. *Eur Respir Rev*. 2015 Sep;24(137):451-61.
- 93) Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. *Drugs Today (Barc)*. 2015 Aug;51(8):469-78.
- 94) Liccardi G, Salzillo A, Calzetta L, Pignatti P, Rogliani P. Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life? *Allergol Immunopathol (Madr)*. 2015 Nov 16. pii: S0301-0546(15)00121-4.

- 95) Cazzola M, Calzetta L, Rogliani P, Puxeddu E, Facciolo F, Matera MG. Interaction between corticosteroids and muscarinic antagonists in human airways. *Pulm Pharmacol Ther.* 2016 Feb;36:1-9
- 96) Liccardi G, Salzillo A, Calzetta L, Piccolo A, . How many systemic reactions to skin prick tests could be preventable in defined conditions? *Ann Allergy Asthma Immunol.* 2016 Feb;116(2):174
- 97) Cazzola M, Rogliani P, Ora J, Matera MG. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2016 May;17(7):977-88
- 98) Calzetta L, Rogliani P, Matera MG, Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. *Chest* 2016 May;149(5):1181-96
- 99) Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. *Drug Saf.* 2016 Jun;39(6):501-8
- 100) Liccardi G, Salzillo A, Calzetta L, Piccolo A, Menna G, Rogliani P. Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies. *Eur Ann Allergy Clin Immunol.* 2016 Mar;48(2):61-4
- 101) Liccardi G, Salzillo A, Calzetta L, Piccolo A, Rogliani P. Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection? *J Allergy Clin Immunol.* 2016 May;137(5):1621-2
- 102) Cazzola M, Calzetta L, Rogliani P, Matera MG. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. *Expert Opin Drug Discov.* 2016 May 21:1-12
- 103) D'Antonio S, Rogliani P, Paone G, Altieri A, Alma MG, Cazzola M, Puxeddu E. An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. *Int J Mycobacteriol.* 2016 Jun;5(2):244-7